Next Article in Journal
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
Next Article in Special Issue
Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy
Previous Article in Journal
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
Previous Article in Special Issue
Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies

Purine-Metabolising Enzymes and Apoptosis in Cancer

Dipartimento di Biologia, Unità di Biochimica, Via S. Zeno 51, 56127 Pisa, Italy
Dipartimento di Biologia, Unità di Fisiologia Generale, Via S. Zeno 31, 56127 Pisa, Italy
Author to whom correspondence should be addressed.
These authors equally contributed to the work.
Cancers 2019, 11(9), 1354;
Received: 24 July 2019 / Revised: 3 September 2019 / Accepted: 7 September 2019 / Published: 12 September 2019
(This article belongs to the Special Issue Apoptosis in Cancer)
The enzymes of both de novo and salvage pathways for purine nucleotide synthesis are regulated to meet the demand of nucleic acid precursors during proliferation. Among them, the salvage pathway enzymes seem to play the key role in replenishing the purine pool in dividing and tumour cells that require a greater amount of nucleotides. An imbalance in the purine pools is fundamental not only for preventing cell proliferation, but also, in many cases, to promote apoptosis. It is known that tumour cells harbour several mutations that might lead to defective apoptosis-inducing pathways, and this is probably at the basis of the initial expansion of the population of neoplastic cells. Therefore, knowledge of the molecular mechanisms that lead to apoptosis of tumoural cells is key to predicting the possible success of a drug treatment and planning more effective and focused therapies. In this review, we describe how the modulation of enzymes involved in purine metabolism in tumour cells may affect the apoptotic programme. The enzymes discussed are: ectosolic and cytosolic 5′-nucleotidases, purine nucleoside phosphorylase, adenosine deaminase, hypoxanthine-guanine phosphoribosyltransferase, and inosine-5′-monophosphate dehydrogenase, as well as recently described enzymes particularly expressed in tumour cells, such as deoxynucleoside triphosphate triphosphohydrolase and 7,8-dihydro-8-oxoguanine triphosphatase. View Full-Text
Keywords: purine salvage; apoptosis; CD73; cN-II; ADA; PNP; HPRT; IMPDH; SAMHD1; MTH1 purine salvage; apoptosis; CD73; cN-II; ADA; PNP; HPRT; IMPDH; SAMHD1; MTH1
Show Figures

Graphical abstract

MDPI and ACS Style

Camici, M.; Garcia-Gil, M.; Pesi, R.; Allegrini, S.; Tozzi, M.G. Purine-Metabolising Enzymes and Apoptosis in Cancer. Cancers 2019, 11, 1354.

AMA Style

Camici M, Garcia-Gil M, Pesi R, Allegrini S, Tozzi MG. Purine-Metabolising Enzymes and Apoptosis in Cancer. Cancers. 2019; 11(9):1354.

Chicago/Turabian Style

Camici, Marcella, Mercedes Garcia-Gil, Rossana Pesi, Simone Allegrini, and Maria Grazia Tozzi. 2019. "Purine-Metabolising Enzymes and Apoptosis in Cancer" Cancers 11, no. 9: 1354.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop